WO2006054623A1 - 新規ピリドンカルボン酸誘導体又はその塩 - Google Patents
新規ピリドンカルボン酸誘導体又はその塩 Download PDFInfo
- Publication number
- WO2006054623A1 WO2006054623A1 PCT/JP2005/021093 JP2005021093W WO2006054623A1 WO 2006054623 A1 WO2006054623 A1 WO 2006054623A1 JP 2005021093 W JP2005021093 W JP 2005021093W WO 2006054623 A1 WO2006054623 A1 WO 2006054623A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- salt
- compound
- acid derivative
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention has excellent antibacterial action and high! ⁇ ⁇ ⁇ ⁇ It relates to pyridonecarboxylic acid derivatives or salts thereof having bioavailability.
- Patent Document 1 JP-A-53-141286
- Patent Document 2 Japanese Patent Laid-Open No. 55-031042
- Patent Document 3 Japanese Patent Application Laid-Open No. 57-046986
- Patent Document 4 Japanese Patent Application Laid-Open No. 58-076667
- Patent Document 5 Japanese Patent Laid-Open No. 60-228479
- Patent Document 6 Pamphlet of International Publication No. 97Z11068
- Patent Document 7 Pamphlet of International Publication No. 01Z02390
- An object of the present invention is to provide a drug having excellent antibacterial activity, low toxicity, improved bioavailability, and low serum protein binding rate.
- the present inventors further examined the above pyridonecarboxylic acid derivative having a substituted pyridyl group at the 1-position and an aminoazetidyl group at the 7-position, and found that on the azetidine ring. Even when the lipid chain is increased by increasing the alkyl chain to the amino group, the serum protein binding rate is higher than the compound represented by the following general formula (1) into which isopropyl group and tert-butyl group are introduced. It was found that the no-o-beirability could be improved without rising. Further, the present inventors have found that a compound represented by the following general formula (2) is useful as a synthetic intermediate for the compound represented by the general formula (1).
- R 1 represents a methyl group, a fluorine atom or a chlorine atom
- R 2 represents a hydrogen atom or a lower alkyl group
- R 3 represents an isopropyl group or a tert butyl group
- R 4 represents a methyl group.
- R 5 represents a fluorine atom or a chlorine atom
- the present invention relates to 1 (6 amino-3,5 difluoropyridine-2-yl) -6 fluoro 7- (3-isopropylaminoazetidine 1-yl) 8-methyl 4-oxo 1,4-dihydroquinoline-3-strong rubonic acid or its salt.
- the present invention also relates to a pharmaceutical comprising the above-described pyridonecarboxylic acid derivative and a salt thereof as an active ingredient.
- the present invention also relates to an antibacterial agent comprising the above pyridonecarboxylic acid derivative and a salt thereof as an active ingredient.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising the pyridonecarboxylic acid derivative or a salt thereof and a pharmaceutically acceptable carrier.
- the present invention also relates to the use of the pyridonecarboxylic acid derivative or a salt thereof for producing a medicament.
- the present invention also relates to a method for treating an infectious disease, characterized by administering the pyridonecarboxylic acid derivative or a salt thereof.
- R 1 represents a methyl group, a fluorine atom or a chlorine atom
- R ° represents an isopropyl group or a tert-butyl group
- R 4 represents a methyl group or a halogen atom
- R 5 represents a fluorine atom or a chlorine atom
- R 6 represents a hydrogen atom or a carboxy protecting group
- R 7 represents —NR 8 (where, R 2 represents a hydrogen atom or a lower alkyl group, and R 8 represents a hydrogen atom or an amino protecting group. However, R 6 and R 8 are not hydrogen atoms at the same time. ).
- an antibacterial agent having extremely excellent antibacterial activity, no phototoxicity, high bioavailability and low serum protein binding rate is provided. Can do.
- the pyridonecarboxylic acid derivative represented by the general formula (1) of the present invention or a salt thereof is useful as an antibacterial agent
- the salt is useful as an intermediate for producing the pyridonecarboxylic acid derivative represented by the formula (1).
- the lower alkyl group represented by R 2 includes 1 to 6 straight chain or branched chain alkyl groups, specifically, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pentyl group, hexyl group, etc. .
- linear or branched alkyl groups having 1 to 3 carbon atoms such as a methyl group, an ethyl group, a propyl group, and an isopropyl group are preferable, and a methyl group is particularly preferable.
- Examples of the halogen atom represented by R 4 include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom, with a chlorine atom and a bromine atom being particularly preferred.
- the carboxy-protecting group represented by R 6 includes an ester residue of a carboxylic acid ester, and includes any that can be cleaved relatively easily to give a corresponding free carboxy group,
- a lower alkyl group having 1 to 6 carbon atoms such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pentyl group, hexyl group; 1-probe group, butyr group, pentyl group, hexyl group, heptul group, etc., C1-C8 alkenyl group; benzyl group etc., C7-C11 aralkyl group ; Products that leave by mild conditions such as hydrolysis or catalytic reduction of aryl groups such as phenyl groups, naphthyl groups, etc., having 6 to 14 carbon atoms, or cetoxymethyl groups, bivalyloxy Lower al
- Examples of the amino protecting group represented by R 8 include hydrolysis and catalytic reduction of a benzyl group, 1-phenylethyl group, tert-butoxycarbol group, benzyloxycarbonyl group, benzhydryl group, and the like. And the like that are easily detached.
- R 1 is a fluorine atom
- R 2 is a hydrogen atom or a methyl group
- R 4 is a bromine atom or a methyl group
- R 5 is a fluorine atom.
- the pyridonecarboxylic acid derivative represented by the general formula (1) or (2) can form an acid, a base and an acid addition salt, or a base addition salt.
- the acid addition salt include ( B) Salts with mineral acids such as hydrochloric acid and sulfuric acid; (Mucous) salts with organic carboxylic acids such as formic acid, acetic acid, citrate, trichloro-acetic acid, trifluoroacetic acid, fumaric acid and maleic acid; Acid, benzene sulfonic acid, p Toluene sulfonic acid, mesitylene sulfonic acid, naphthalene sulfonic acid and other salts with sulfonic acids, and as base addition salts, for example, (b) salts with alkali metals such as sodium and potassium , (Mouth ') Salts with alkaline earth metals such as calcium and magnesium, (Ha,) ammonium salts, (2,) Trimethyl
- the pyridonecarboxylic acid derivative represented by the formula (1) or (2) or a salt thereof can exist not only as an unsolvated type but also as a hydrate or a solvate. . Therefore, the book In the invention, all crystal forms and hydrates or solvates thereof are included.
- Such a pyridonecarboxylic acid derivative (1) and its production intermediate (2) are as follows.
- L ⁇ L 2 represents a halogen atom such as a fluorine atom or a chlorine atom
- R 9 represents an alkyl group having 15 carbon atoms
- R 5 R 6 and R 7 are the same as described above.
- orthoformate [(R 90 ) CH] is reacted with compound (A) and amino compound (B) is further reacted to form compound (C), or acetal is converted to compound (A).
- the amino compound (B) is reacted to obtain a compound (C), which is then subjected to a cyclization reaction to form a quinoline ring to obtain a compound (D), which is hydrolyzed, and further optionally. It is subjected to a deprotection reaction such as a reduction reaction to obtain compound (E).
- a pyridonecarboxylic acid derivative (1) can be obtained by amination reaction with the azetidine derivative (F).
- a pyridonecarboxylic acid derivative (2) is obtained by amination reaction between the compound (D) and the azetidine derivative (F), followed by a hydrolysis reaction, and if desired, a deprotection reaction such as a reduction reaction. To give a pyridonecarboxylic acid derivative (1).
- the reaction of the compound (A) with orthoformates is usually carried out at 0 to 160 ° C, preferably 50 to 150 ° C, and the reaction time is usually 10 minutes to 48 hours, preferably 1 to: LO time.
- the amount of orthoformate used is preferably equimolar or more, especially about 1 to 10 times the molar amount relative to compound (A).
- the amount of the reaction aid is preferably equimolar or more, especially about 1 to 10 times mol for the compound (A).
- the amount of the amino compound (B) used is based on the compound (A).
- equimolar or more, particularly equimolar to 2-fold molar is preferred.
- the solvent used here may be any solvent that does not affect the reaction, for example, aromatic hydrocarbons such as benzene, toluene, xylene, etc .; jetyl ether, tetrahydrofuran, 1, 4 Ethers such as dioxane, monoglyme and diglyme; Aliphatic hydrocarbons such as pentane, hexane, heptane and lignin; Halogenated hydrocarbons such as methylene chloride, black mouth form and tetrasalt carbon; Aprotic polar solvents such as N, N dimethylformamide and dimethyl sulfoxide; alcohols such as methanol, ethanol and propanol.
- aromatic hydrocarbons such as benzene, toluene, xylene, etc .
- jetyl ether, tetrahydrofuran, 1, 4 Ethers such as dioxane, monoglyme and diglyme
- Aliphatic hydrocarbons such as pent
- compound (A) is reacted with acetals such as N, N dimethylformamide dimethylacetal, N, N dimethylformamide jetylacetal, and then reacted with alumino compound (B).
- acetals such as N, N dimethylformamide dimethylacetal, N, N dimethylformamide jetylacetal
- alumino compound (B) is reacted with compound (C).
- the solvent used in the reaction with the acetals any solvent that does not affect this reaction may be used. Specifically, the same solvents as described above can be used.
- This reaction is normally performed at 0 to 150 ° C.
- the reaction is preferably performed at room temperature to 100 ° C., and the reaction time is usually 10 minutes to 48 hours, preferably 1 to 10 hours.
- the reaction for obtaining compound (D) by subjecting compound (C) to a cyclization reaction is carried out in a suitable solvent in the presence or absence of a basic compound.
- a suitable solvent for example, aromatic hydrocarbons such as benzene, toluene and xylene; jetyl ether, tetrahydrofuran, dioxane, Ethers such as lime and diglyme; Halogenated hydrocarbons such as methylene chloride, black mouth form and carbon tetrachloride; Aprotic polar solvents such as dimethylformamide and dimethyl sulfoxide; Alcohols such as methanol, ethanol and propanol Etc.
- basic compounds used include alkali metals such as metal sodium and metal potassium; metal hydrides such as sodium hydride and calcium hydride; lithium hydroxide, sodium hydroxide, water Inorganic salts such as potassium carbonate, sodium carbonate, potassium carbonate; sodium methoxide, sodium ethoxide, alkoxides such as potassium tert-butoxide, metal fluorides such as sodium fluoride and potassium fluoride; triethylamine, 1, 8 Organic bases such as diazabicyclo [5.4.0] undecene (DBU).
- the temperature of this reaction is usually 0 to 200 ° C, preferably room temperature to 180 ° C, and the reaction is usually completed in 5 minutes to 24 hours.
- the amount of the basic compound used is equimolar or more, preferably equimolar to 2-fold molar relative to compound (C).
- the compound (E) can be obtained by hydrolyzing the compound (D) and subjecting it to a reduction reaction as necessary.
- any of the reaction conditions used in ordinary hydrolysis can be applied.
- basic compounds such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate; hydrochloric acid, sulfuric acid , Mineral acids such as hydrobromic acid; or p in the presence of organic acids such as toluenesulfonic acid, alcohols such as water, methanol, ethanol, propanol, ethers such as tetrahydrofuran, dioxane, acetone, methyl
- a ketone such as ethyl ketone
- a solvent such as acetic acid or a mixed solvent thereof.
- the reduction reaction is a catalytic reduction, such as palladium carbon, palladium hydroxide carbon, etc.
- a catalytic reduction such as palladium carbon, palladium hydroxide carbon, etc.
- hydrogen or ammonium formate as a hydrogen source
- a solvent such as methanol, ethanol or other alcohol or acetic acid
- the reaction can be carried out preferably for 1 to 5 hours.
- the pyridone-powered rubonic acid derivative (1) of the present invention can be obtained by reacting the compound (E) with the azetidine derivative (F).
- This reaction involves aromatic hydrocarbons such as benzene, toluene and xylene; alcohols such as methanol and ethanol; ethers such as tetrahydrofuran, dioxane and monoglyme; methylene chloride, chloroform, tetrachloride.
- Halogenated hydrocarbons such as carbon; aprotic polar solvents such as dimethylformamide, dimethyl sulfoxide, and N-methylpyrrolidone; do not affect the reaction such as acetonitrile, pyridine, etc.
- Acid agents such as sodium carbonate, calcium carbonate, lithium hydroxide, triethylamine, 1,8-diazabicyclo [5.4.0] undecene (DBU), N-methylpyrrolidine, 1, 1, 3, 3-tetra
- an additive agent such as lithium chloride, perchloric acid Lithium, triflumizole Ruo b lithium methanesulfonate of any presence, carried out at room temperature ⁇ 160 ° C.
- the reaction time is several minutes to 48 hours, preferably 10 minutes to 24 hours.
- the amount of the azetidine derivative to be used is equimolar or more, preferably equimolar to 5-fold molar to the compound (E).
- the pyridonecarboxylic acid derivative (1) of the present invention can be converted into an acid addition salt or a base addition salt according to a conventional method.
- the pyridonecarboxylic acid derivative (1) of the present invention is converted into a mineral acid such as hydrochloric acid or sulfuric acid, formic acid, acetic acid, quenoic acid, trichlorodiacetic acid in an alcohol such as methanol or ethanol, or in a polar solvent such as water.
- Organic carboxylic acids such as trifluoroacetic acid, fumaric acid, maleic acid, etc., methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylene norephonic acid, snorphonic acid such as naphthalene norephonic acid, Basic compounds such as potassium carbonate, calcium hydroxide, magnesium hydroxide, ammonium, trimethylamine, triethylamine, tributylamine, pyridine, N, N-dimethyl Aniline, N-methylbiperidine, N-methylmorpholine, jetylamine, cyclohexylamine, pro-power-in, dibenzylamine, N-benzyl-1-beta-phenethylamine, 1-ephenamine, ⁇ , ⁇ , didipenoleethylenediamine, ⁇ —Methinore D—This is carried out by heating at room temperature or appropriately in the presence of a nitrogen
- the raw material compound (i) can be produced, for example, by the method described in the following literature or a method analogous thereto.
- the raw material composite (B) can be produced by any method. For example, it can be produced by the reaction described in JP-A-11-322715.
- the compound obtained in each of the above steps can be isolated and purified according to a conventional method. Depending on the isolation and purification conditions, it can be obtained in the form of a salt, a free carboxylic acid or a free amine, which are converted to each other as desired to produce the desired form of the compound of the present invention.
- the pyridonecarboxylic acid derivative (1) or a salt thereof having a substituted pyridyl group at the 1-position and an isopropylaminoazetidinyl group or a tert-butylaminoazetidinyl group at the 7-position thus obtained is As shown in Examples 1 to 4, the compounds described in International Publication No. 97Z11068 and International Publication No. 01Z02390 (Comparative Compound 1 to 4) have excellent antibacterial activity and quinolone-specific toxicity. While retaining the property of not exhibiting phototoxicity The bioavailability is much higher than that of the compound, and the increase in the serum protein binding rate is suppressed.
- Serum protein refers to albumin (HAS), acidic glycoprotein (AGP), and lipoprotein (AFP) present in blood.
- Serum protein binding rate refers to the amount of serum protein relative to the total amount of compounds in blood. The ratio of the amount of compound that binds.
- the pyridonecarboxylic acid derivative (1) or a salt thereof of the present invention is mainly an antibacterial agent, that is, a pharmaceutical, animal medicine, fish disease medicine, agricultural chemical, food preservative for prevention or treatment of infectious diseases. Useful as such.
- a pharmaceutically acceptable carrier is added as necessary to form various pharmaceutical compositions of parenteral preparations such as injection, rectal and eye drops, or oral preparations. be able to.
- Examples of the dosage form for injection include pharmaceutically acceptable sterile or water-insoluble systems, suspensions and emulsions.
- suitable non-aqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
- Such compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- These compositions are sterilized, for example, by filtration through a bacteria-retaining filter, or by mixing the sterilant in the form of a sterile solid composition that can be dissolved in a sterilant or some other sterile injectable medium immediately before use. be able to.
- a preparation for eye drop administration may contain a solubilizer, a preservative, an isotonic agent, a thickener and the like.
- Examples of solid preparations for oral administration include capsules, tablets, pills, powders and granules.
- the compound of the present invention is generally mixed with at least one inert diluent such as sucrose, lactose or starch.
- This formulation may also be used for normal formulation! Additional materials other than inert diluents such as lubricants (eg, magnesium stearate) may be used.
- lubricants eg, magnesium stearate
- Tablets and pills may be enteric coated.
- Liquid formulations for oral administration include inert diluents commonly used by those skilled in the art, Examples include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing water.
- the composition may also contain adjuvants such as wetting agents, emulsifying agents, suspending agents and sweetening, flavoring and flavoring agents.
- Formulations for rectal administration may preferably contain excipients such as cocoa butter or suppository waxes in addition to the compound of the present invention!
- the dosage of the pyridonecarboxylic acid derivative of the present invention will vary depending on the nature of the compound, the route of administration, the desired duration of treatment and other factors, but is generally about 0 per day.
- this daily dose can be divided into 2 to 4 doses.
- N-Isopropylazetidine mono-3-ylamine dihydrochloride 374 mg, 1- (6-aminoamino 3,5 difluoropyridine 1-2-yl) 8 Bromo 6, 7 difluoro 4- 4-oxo 1, 4- Dihydroquinoline-3-strong sulfonic acid (518 mg), N-methylpyrrolidine (0.8 mL), lithium chloride (500 mg) and dimethyl sulfoxide (1.5 mL) were mixed, and the mixture was heated and stirred at 50 ° C for 4.5 hours. After standing to cool, add 10 mL of jetillite, stir, remove the supernatant, and perform the same operation.
- Test examples 1 to 4 show the antibacterial activity, phototoxicity test, serum protein binding rate and pharmacokinetics of the compounds of the present invention.
- comparative compounds the following compounds described in International Patent Publication No. 97Z 11068 and International Patent Publication No. 01Z02390 were used.
- Comparative compound 1 1— (6 amino 3,5 difluoropyridine 2 yl) 8 bromo 6 fluoro 7— (3 methylaminoazetidine 1 yl) 4 oxo 1,4-dihydroquinoline 3-carboxylic acid
- Comparative compound 2 1— (6 amino 3,5 difluoropyridine 2 yl) 8 bromo 7— (3 ethylaminoazetidine 1 yl) 6 Fluoro 4 oxo-1,4— Dihydroquinoline 3-carboxylic acid
- Comparative compound 3 1— (6 amino 3,5 difluoropyridine 2 yl) 8 bromo 6 fluoro 7— (3 methylaminoazetidine 1 yl) 4 oxo 1, 4—dihydroquinoline 3—strength rubonic acid malee Acid salt
- Comparative compound 4 1 (6 amino-3,5 difluoropyridine-2 yl) -8 bromo 7- (3 ethylaminoazetidine 1 yl) 6 fluoro 4 oxo-1,4- dihydroquinoline 3— Power rubonic acid maleate
- the minimum growth inhibitory concentration (MIC : i u gZmL) was measured for the compounds shown in Table 1 according to the Japanese Society of Acupuncture Therapy Standard Method (CHEMOTHERAPY, 29 (1), 76, 1981). The results are shown in Table 1.
- the compound shown in Table 2 was subjected to a phototoxicity test by the following method.
- the protein binding rate of the compounds shown in Table 3 was measured using an ultrafiltration method. Specifically, a 0.5 mg / mL DMSO solution of each compound was diluted with human serum or 0.4% phosphate buffer solution (pH 7.4, containing 0.5% sodium chloride sodium chloride) to a concentration of 5 gZmL. It was adjusted . The human serum solution was incubated at 37 ° C for 30 minutes, and then centrifugally filtered using a filter (pore diameter: 0.22 m). A certain amount of serum filtrate and phosphate buffer solution was injected into HPLC, and the peak area of the compound was determined. The human serum protein binding rate was calculated using Equation 1 below.
- the compound of the present invention showed a low value without an increase in the protein binding rate expected due to an increase in fat solubility.
- the absorbability of the compounds shown in Table 4 was investigated. That is, fast for 16-17 hours A 0.5% methylcellulose suspension (lOmgZkg) of the test compound was orally administered to male 2-4 year-old male beagle dogs. After administration, blood was collected at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours to obtain serum. The test compound concentration in serum was measured and the absorbability was evaluated. The results obtained are shown in Table 4.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK05806666.3T DK1813610T3 (da) | 2004-11-17 | 2005-11-17 | Nye pyridoncarboxylsyrederivater eller salte deraf |
BRPI0517643-3A BRPI0517643A (pt) | 2004-11-17 | 2005-11-17 | derivados de ácido piridono-carboxìlico ou seus sais |
MX2007005892A MX2007005892A (es) | 2004-11-17 | 2005-11-17 | Derivados de acido piridonacarboxilico novedosos y sales de los mismos. |
US11/719,547 US7713997B2 (en) | 2004-11-17 | 2005-11-17 | Pyridonecarboxylic acid derivatives or salts thereof |
PL05806666T PL1813610T3 (pl) | 2004-11-17 | 2005-11-17 | Nowe pochodne kwasu pirydynokarboksylowego lub ich sole |
DE602005023513T DE602005023513D1 (de) | 2004-11-17 | 2005-11-17 | Neue pyridoncarboxylsäurederivative oder salze daraus |
JP2006545116A JP3995705B2 (ja) | 2004-11-17 | 2005-11-17 | 新規ピリドンカルボン酸誘導体又はその塩 |
CA002588034A CA2588034A1 (en) | 2004-11-17 | 2005-11-17 | Pyridonecarboxylic acid derivatives or salts thereof |
AT05806666T ATE480535T1 (de) | 2004-11-17 | 2005-11-17 | Neue pyridoncarboxylsäurederivative oder salze daraus |
AU2005307447A AU2005307447B2 (en) | 2004-11-17 | 2005-11-17 | Novel pyridonecarboxylic acid derivatives or salts thereof |
EP05806666A EP1813610B1 (en) | 2004-11-17 | 2005-11-17 | Novel pyridonecarboxylic acid derivatives or salts thereof |
SI200531160T SI1813610T1 (sl) | 2004-11-17 | 2005-11-17 | Novi derivati piridonkarboksilne kisline ali njihove soli |
CN2005800394017A CN101061109B (zh) | 2004-11-17 | 2005-11-17 | 吡啶酮羧酸衍生物或其盐 |
HK08100117.0A HK1109616A1 (en) | 2004-11-17 | 2008-01-07 | Pyridonecarboxylic acid derivatives or salts thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-333244 | 2004-11-17 | ||
JP2004333244 | 2004-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006054623A1 true WO2006054623A1 (ja) | 2006-05-26 |
Family
ID=36407161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/021093 WO2006054623A1 (ja) | 2004-11-17 | 2005-11-17 | 新規ピリドンカルボン酸誘導体又はその塩 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7713997B2 (ja) |
EP (1) | EP1813610B1 (ja) |
JP (1) | JP3995705B2 (ja) |
KR (1) | KR20070084159A (ja) |
CN (1) | CN101061109B (ja) |
AT (1) | ATE480535T1 (ja) |
AU (1) | AU2005307447B2 (ja) |
BR (1) | BRPI0517643A (ja) |
CA (1) | CA2588034A1 (ja) |
CY (1) | CY1110898T1 (ja) |
DE (1) | DE602005023513D1 (ja) |
DK (1) | DK1813610T3 (ja) |
ES (1) | ES2349278T3 (ja) |
HK (1) | HK1109616A1 (ja) |
MX (1) | MX2007005892A (ja) |
PL (1) | PL1813610T3 (ja) |
PT (1) | PT1813610E (ja) |
RU (1) | RU2379304C2 (ja) |
SI (1) | SI1813610T1 (ja) |
WO (1) | WO2006054623A1 (ja) |
ZA (1) | ZA200704862B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473616A4 (en) * | 2016-06-15 | 2020-02-19 | Wakunaga Pharmaceutical Co., Ltd. | NEW PYRIDONE CARBONIC DERIVATIVE OR SALT THEREOF |
RU2634122C1 (ru) * | 2016-12-14 | 2017-10-24 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Фторхинолоны на основе 4-дезоксипиридоксина |
CN114539213A (zh) * | 2021-08-18 | 2022-05-27 | 广东工业大学 | 一种氟喹诺酮类化合物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997011068A1 (fr) * | 1995-09-22 | 1997-03-27 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives de l'acide pyridone-carboxylique ou leurs sels et agent antibacterien les contenant comme ingredient actif |
WO2001002390A1 (fr) * | 1999-07-01 | 2001-01-11 | Wakunaga Pharmaceutical Co., Ltd. | Derive d'acide quinolinecarboxylique et ses sels |
WO2002058695A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
-
2005
- 2005-11-17 EP EP05806666A patent/EP1813610B1/en not_active Not-in-force
- 2005-11-17 US US11/719,547 patent/US7713997B2/en not_active Expired - Fee Related
- 2005-11-17 PT PT05806666T patent/PT1813610E/pt unknown
- 2005-11-17 AT AT05806666T patent/ATE480535T1/de active
- 2005-11-17 MX MX2007005892A patent/MX2007005892A/es active IP Right Grant
- 2005-11-17 ES ES05806666T patent/ES2349278T3/es active Active
- 2005-11-17 SI SI200531160T patent/SI1813610T1/sl unknown
- 2005-11-17 KR KR1020077010652A patent/KR20070084159A/ko not_active Application Discontinuation
- 2005-11-17 CA CA002588034A patent/CA2588034A1/en not_active Abandoned
- 2005-11-17 ZA ZA200704862A patent/ZA200704862B/xx unknown
- 2005-11-17 RU RU2007122499/04A patent/RU2379304C2/ru not_active IP Right Cessation
- 2005-11-17 CN CN2005800394017A patent/CN101061109B/zh not_active Expired - Fee Related
- 2005-11-17 DK DK05806666.3T patent/DK1813610T3/da active
- 2005-11-17 BR BRPI0517643-3A patent/BRPI0517643A/pt not_active IP Right Cessation
- 2005-11-17 DE DE602005023513T patent/DE602005023513D1/de active Active
- 2005-11-17 AU AU2005307447A patent/AU2005307447B2/en not_active Ceased
- 2005-11-17 JP JP2006545116A patent/JP3995705B2/ja not_active Expired - Fee Related
- 2005-11-17 WO PCT/JP2005/021093 patent/WO2006054623A1/ja active Application Filing
- 2005-11-17 PL PL05806666T patent/PL1813610T3/pl unknown
-
2008
- 2008-01-07 HK HK08100117.0A patent/HK1109616A1/xx not_active IP Right Cessation
-
2010
- 2010-11-12 CY CY20101101020T patent/CY1110898T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997011068A1 (fr) * | 1995-09-22 | 1997-03-27 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives de l'acide pyridone-carboxylique ou leurs sels et agent antibacterien les contenant comme ingredient actif |
WO2001002390A1 (fr) * | 1999-07-01 | 2001-01-11 | Wakunaga Pharmaceutical Co., Ltd. | Derive d'acide quinolinecarboxylique et ses sels |
WO2002058695A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
Also Published As
Publication number | Publication date |
---|---|
DK1813610T3 (da) | 2010-12-06 |
EP1813610B1 (en) | 2010-09-08 |
CY1110898T1 (el) | 2015-06-10 |
EP1813610A1 (en) | 2007-08-01 |
RU2007122499A (ru) | 2008-12-27 |
MX2007005892A (es) | 2007-06-19 |
JP3995705B2 (ja) | 2007-10-24 |
HK1109616A1 (en) | 2008-06-13 |
ATE480535T1 (de) | 2010-09-15 |
ES2349278T3 (es) | 2010-12-29 |
RU2379304C2 (ru) | 2010-01-20 |
AU2005307447B2 (en) | 2011-03-10 |
CN101061109A (zh) | 2007-10-24 |
DE602005023513D1 (de) | 2010-10-21 |
JPWO2006054623A1 (ja) | 2008-05-29 |
SI1813610T1 (sl) | 2010-12-31 |
US7713997B2 (en) | 2010-05-11 |
CA2588034A1 (en) | 2006-05-26 |
KR20070084159A (ko) | 2007-08-24 |
AU2005307447A1 (en) | 2006-05-26 |
US20090149440A1 (en) | 2009-06-11 |
BRPI0517643A (pt) | 2008-10-14 |
PT1813610E (pt) | 2010-10-11 |
CN101061109B (zh) | 2011-05-25 |
ZA200704862B (en) | 2008-12-31 |
EP1813610A4 (en) | 2009-05-20 |
PL1813610T3 (pl) | 2011-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6991213B2 (ja) | Hbv感染の治療のための新規治療薬 | |
JP2742248B2 (ja) | 7−(4−アミノメチル−3−オキシム)ピロリジン置換体を持つ新規なキノリンカルボン酸誘導体およびその製造方法 | |
JP2673937B2 (ja) | 5−アミノ−8−メチル−7−ピロリジニルキノリン−3−カルボン酸誘導体 | |
WO2006054623A1 (ja) | 新規ピリドンカルボン酸誘導体又はその塩 | |
JP3477466B2 (ja) | キノリンカルボン酸誘導体又はその塩 | |
RU2236408C2 (ru) | 1-(6-амино-3,5-дифторпиридин-2-ил)-8-бром-7(3-этил-аминоазетидин-1-ил)-6- фтор-4-оксо-1,4-дигидрохинолин-3-карбоновая кислота, лекарственная композиция и способ лечения на основе этого соединения | |
WO1995021163A1 (fr) | Derive d'acide pyridonecarboxylique substitue par un groupe amino bicyclique, ester et sel de celui-ci, et amine bicyclique utilisee en tant qu'intermediaire pour celui-ci | |
JPH06199835A (ja) | 8−ジフルオロメトキシキノリン−3−カルボン酸誘導体 | |
JPH05345777A (ja) | 7−(4,4−ジアルキル−3−アミノ置換ピロリジニル)キノロン−3−カルボン酸誘導体 | |
EP1156047B1 (en) | 6-substituted-7- heteroquinoxaline carboxylic acid derivatives and addition salts thereof and processes for the preparation of both | |
JPH06145167A (ja) | 8−メトキシ−5−メチルキノリン−3−カルボン酸誘導体 | |
JP2007531775A (ja) | 高増殖状態の処置のためのキノロンカルボン酸誘導体 | |
JPH0770110A (ja) | 5,8−ジメチルキノリン−3−カルボン酸誘導体 | |
JPH0649059A (ja) | 7−(5−アザスピロ〔2,4〕ヘプタン−5−イル)−8−アルコキシキノリン−3−カルボン酸誘導体 | |
JP3354526B2 (ja) | トロバフロキサシン酸塩の製造方法 | |
WO1997031919A1 (fr) | Derives d'acide pyridonecarboxylique et leur intermediaires de synthese | |
WO1996011194A1 (fr) | Derive d'acide pyridonecarboxylique et intermediaire servant a effectuer sa synthese | |
JP2951726B2 (ja) | ピリドンカルボン酸誘導体およびその合成中間体 | |
JPS63284171A (ja) | キノリン−3−カルボン酸誘導体 | |
JPH0649060A (ja) | 5−アミノ−7−(5−アザスピロ〔2,4〕ヘプタン−5−イル)キノリン−3−カルボン酸誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006545116 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005806666 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005307447 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3008/DELNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005307447 Country of ref document: AU Date of ref document: 20051117 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077010652 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2588034 Country of ref document: CA Ref document number: MX/a/2007/005892 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580039401.7 Country of ref document: CN Ref document number: 11719547 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007122499 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005806666 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0517643 Country of ref document: BR |